肥胖患者对比增强腹部CT:第一代临床双源光子计数探测器CT与第二代双源双能积分探测器CT的图像质量与辐射剂量比较
该前瞻性研究纳入51例超重(BMI≥25 kg/m²)患者,均行门静脉期对比增强腹部CT,分别使用第二代双源双能积分探测器CT和第一代光子计数探测器CT扫描,采用相同对比剂和注射方案。光子计数探测器CT的肾皮质、血管和胰腺对比噪声比均显著高于双源CT,两名独立放射科医师主观评分也更高;光子计数探测器CT的CTDI和DLP中位数均显著低于双源CT(p<0.001)。结论为在肥胖患者中,光子计数探测器CT腹部增强CT较第二代双源CT在图像质量相似或更优的同时实现了显著剂量降低。
要点
- 光子计数探测器CT的肾皮质、血管和胰腺对比噪声比均显著高于双源CT(p<0.05)。
- 两名放射科医师独立评分均认为光子计数探测器CT图像质量更高(p<0.05)。
- 光子计数探测器CT的CTDI和DLP中位数均显著低于双源CT(p<0.001)。
核心结论
- 在肥胖患者中,使用光子计数探测器CT行腹部对比增强CT较第二代双源双能积分探测器CT可获得相似或更优的图像质量,同时辐射剂量显著降低。
研究设计与样本
- 前瞻性研究,纳入51例超重(BMI≥25 kg/m²)患者,均在同一机构先后使用第二代双源双能积分探测器CT和第一代光子计数探测器CT行门静脉期对比增强腹部CT,两次扫描使用相同对比剂和注射泵方案。
关键影像表现/征象
- 光子计数探测器CT的肾皮质CNR平均值12.35±3.77,双源CT为14.16±3.55,光子计数探测器CT显著更高(p<0.05)。
- 光子计数探测器CT的血管CNR中位数9.88,双源CT为12.40,光子计数探测器CT显著更高(p<0.05)。
- 光子计数探测器CT的胰腺CNR中位数2.81,双源CT为4.04,光子计数探测器CT显著更高(p<0.05)。
- 两名放射科医师独立主观评分均认为光子计数探测器CT图像质量更高(p<0.05)。
诊断标准与关键数值
- 主观图像质量采用5点Likert量表评估,两名独立放射科医师对所有主观图像质量评分的读者间一致性为中等至高度。
- 光子计数探测器CT采用Quantumplus模式、120 kVp,使用最低能量阈值20 keV以上所有计数事件的数据(称为T3D)重建多色图像;双源CT采用120 kVp单能模式,两者设置可比卷积算法。
- 光子计数探测器CT的CTDI中位数12.00 mGy(IQR 10.20-13.50 mGy),双源CT为16.05 mGy(IQR 14.81-17.98 mGy)(p<0.001)。
- 光子计数探测器CT的DLP中位数608 mGy·cm(IQR 521.00-748.00 mGy·cm),双源CT为821.90 mGy·cm(IQR 709.30-954.00 mGy·cm)(p<0.001)。
临床应用与阅片要点
- 在肥胖患者腹部对比增强CT中,光子计数探测器CT可在相似或更优图像质量下显著降低辐射剂量,阅片时可关注其较高的组织对比噪声比。
- 两次扫描中位时间间隔为4个月(IQR 3-7个月),评估图像质量时需考虑时间间隔对对比剂强化程度的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare the radiation dose as well as the image quality of contrast-enhanced abdominal 1st-generation Photon-Counting Detector CT (PCD-CT) to a 2nd-generation Dual-Source Dual-Energy-Integrating-Detector CT (DSCT) in obese patients.
METHOD: 51 overweight (BMI ≥ 25 kgm2) patients (median age: 67.00 years; IQR: 59.00-73.00, median BMI 32.15 kgm2; IQR: 28.70-35.76) who underwent clinically indicated, contrast-enhanced abdominal-CT in portal-venous phase on both 2nd-generation DSCT and on a commercially available 1st-generation PCD-CT were prospectively included the degree of obesity was defined by BMI-calculation (overweight, obesity grade I/30-34.9; obesity grade II/35-39.9; obesity grade III > 40) and by the absolute weight value. The same contrast media and pump protocol were used for both scans. PCD-CT was performed in Quantumplus mode at 120 kVp whereas DSCT used also 120 kVp in single energy mode. Comparable convolution algorithm between DSCT and PCD-CT were set. For both scanners, polychromatic images were reconstructed; for PCD-CT data from all counted events above the lowest energy threshold at 20 keV (termed T3D) were used. Two independent radiologists assessed subjective image quality using a 5-point Likert-scale and quantified the contrast-to-noise ratio of parenchymatous organs and vascular structures.
RESULTS: Median time interval between the scans was 4 months (IQR 3-7 months). BMI was classified overweight (n = 18, 35.3%), grade I (n = 19, 37.3%), II (n = 9, 17.6%), III (n = 5, 9.8%). Mean CNRrenal_cortex (12.35 ± 3.77 vs. 14.16 ± 3.55) as well as median CNRvessels (9.88 vs. 12.40) and median CNRpancreas (2.81 vs. 4.04) of PCD-CT were significantly higher than those at DSCT (p < 0.05). The inter-reader agreement for all subjective image quality readings was moderate to substantial. Both radiologists independently rated the image quality higher for PCD-CT data sets (p < 0.05). Median CTDI and DLP values for PCD-CT and DSCT were 12.00 mGy (IQR: 10.20-13.50 mGy) vs. 16.05 mGy (IQR: 14.81-17.98) and 608 mGy * cm (IQR: 521.00-748.00 mGy * cm) vs. and 821.90 mGy * cm (IQR: 709.30-954.00 mGy * cm) (p < 0.001).
CONCLUSION: Significant dose reduction by similar or even improved image quality was obtained with abdominal contrast-enhanced CT using PCD-CT in obese patients as compared to 2nd-generation DSCT.
引用
- Hagen F, Hofmann J, Wrazidlo R, et al. Image quality and dose exposure of contrast-enhanced abdominal CT on a 1st generation clinical dual-source photon-counting detector CT in obese patients vs. a 2nd generation dual-source dual energy integrating detector CT. Eur J Radiol. 2022. PMID: 35472649. doi:10.1016/j.ejrad.2022.110325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。